PRA Health Sciences (NASDAQ:PRAH) received a $87.00 price target from equities researchers at Mizuho in a research note issued to investors on Friday, December 1st, Marketbeat.com reports. The firm presently has a “buy” rating on the medical research company’s stock. Mizuho’s price objective suggests a potential downside of 4.47% from the company’s previous close.
Several other research firms have also recently weighed in on PRAH. SunTrust Banks reiterated a “buy” rating and issued a $101.00 price target on shares of PRA Health Sciences in a report on Friday, October 27th. Credit Suisse Group reiterated an “outperform” rating and issued a $90.00 price target (up previously from $84.00) on shares of PRA Health Sciences in a report on Monday, October 16th. KeyCorp reiterated a “buy” rating and issued a $93.00 price target (up previously from $86.00) on shares of PRA Health Sciences in a report on Monday, October 30th. Jefferies Group reiterated a “buy” rating and issued a $95.00 price target on shares of PRA Health Sciences in a report on Thursday, October 26th. Finally, Robert W. Baird reiterated a “buy” rating and issued a $88.00 price target on shares of PRA Health Sciences in a report on Monday, October 9th. One investment analyst has rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $90.46.
Shares of PRA Health Sciences (NASDAQ PRAH) traded up $0.01 during trading hours on Friday, reaching $91.07. 300,845 shares of the company’s stock traded hands, compared to its average volume of 518,219. The company has a market capitalization of $5,770.45, a P/E ratio of 50.88, a PEG ratio of 1.57 and a beta of 0.40. PRA Health Sciences has a 1 year low of $54.08 and a 1 year high of $92.00. The company has a debt-to-equity ratio of 1.38, a current ratio of 1.01 and a quick ratio of 1.01.
In related news, Director Matthew P. Young sold 5,115 shares of the stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $79.90, for a total transaction of $408,688.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 2.10% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in PRAH. Capital Research Global Investors boosted its holdings in PRA Health Sciences by 318.3% during the second quarter. Capital Research Global Investors now owns 2,175,340 shares of the medical research company’s stock worth $163,172,000 after purchasing an additional 1,655,336 shares during the last quarter. BlackRock Inc. boosted its holdings in PRA Health Sciences by 28.2% during the second quarter. BlackRock Inc. now owns 3,662,954 shares of the medical research company’s stock worth $274,759,000 after purchasing an additional 805,573 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in PRA Health Sciences by 55.8% during the third quarter. Wells Fargo & Company MN now owns 1,207,069 shares of the medical research company’s stock worth $91,943,000 after purchasing an additional 432,449 shares during the last quarter. Hood River Capital Management LLC boosted its holdings in PRA Health Sciences by 80.3% during the second quarter. Hood River Capital Management LLC now owns 619,924 shares of the medical research company’s stock worth $46,500,000 after purchasing an additional 276,045 shares during the last quarter. Finally, Stephens Investment Management Group LLC boosted its holdings in PRA Health Sciences by 236.9% during the third quarter. Stephens Investment Management Group LLC now owns 391,672 shares of the medical research company’s stock worth $29,834,000 after purchasing an additional 275,414 shares during the last quarter. Institutional investors and hedge funds own 98.22% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “PRA Health Sciences (PRAH) Given a $87.00 Price Target by Mizuho Analysts” was first reported by American Banking and Market News and is owned by of American Banking and Market News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/12/30/pra-health-sciences-prah-given-a-87-00-price-target-by-mizuho-analysts.html.
PRA Health Sciences Company Profile
PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.
